Introduction {#sec1}
============

Salicylate use as a medicinal agent dates back to antiquity, and to this date, aspirin (acetylsalicylic acid, ASA) remains one of the most frequently used pharmaceuticals worldwide ([@ref1]). In the late 1800s, German Chemist Felix Hoffmann was credited with the synthesis of aspirin ([@ref33]), which propelled its use for a variety of maladies. To date, its importance in medical therapeutic approaches continues to increase ([@ref23]; [@ref24]). Aspirin's main use has been for fever, pain, and inflammation reduction ([@ref30]). Recently, aspirin has been shown to have effects as a low-dose therapeutic for primary and secondary prevention of cardiovascular diseases ([@ref1]). Aspirin demonstrated a significant reduction in non-fatal myocardial infarction (MI) and transient ischemic attack by approximately 50% ([@ref28]; [@ref26]); due to these astonishing results, it is now recommended prophylactilly for all members of the population over 40. More recently, aspirin has been shown to have a chemoprotective effect for colorectal cancer, when taken at low dose for five or more years ([@ref20]). Outcomes from these studies have shown at least a 27% reduction in risk of colorectal cancer ([@ref27]). Furthermore, studies now show that similar low-dose aspirin consumption for extended periods can also reduce risk of melanoma ([@ref11]; [@ref35]), and also pancreatic cancer ([@ref22]). These protective effects have been suggested to be *via* the inhibition of the COX enzymes, which further reduces inflammatory and immune responses, and is one of the main mechanisms involved in decreasing tumor risk of colonic malignancies ([@ref20]). The effect of aspirin varies by dose: at low dosage (\<100 mg per day), aspirin affects the platelets by the irreversible inhibition of the cyclooxygenases type 1 (COX1), ultimately leading to an inhibition of thromboxane A (TXA) ([@ref8]); at higher dosage (650 mg--8 g per day), aspirin fulfills characteristics of an analgesic, antipyretic, and anti-inflammatory by inhibiting COX1 and COX2, which leads to a blockage of prostaglandin synthesis ([@ref1]).

Despite all of these advantages, aspirin has in certain cases been shown to have severe adverse effects such as abdominal pain, dyspepsia, nausea, vomiting, and allergies ([@ref1]). In the stomach, aspirin can be responsible for severe damage to the mucosa within the GI tract, leading to an increased risk of ulcer formation ([@ref28]; [@ref14]) and raising the number of major gastric bleeding events by more than 50% in patients taking low-dose aspirin ([@ref20]). The inhibition of prostaglandin synthesis has been thought to be the primary reason for these gastrointestinal adverse effects ([@ref29]). Aspirin has the ability to bind and acetylate prostaglandinendoperoxide synthase 1 (PTGS1 = COX1) and 2 (PTGS2 = COX2) irreversibly ([@ref8]; [@ref27]). These enzymes convert arachidonic acid into prostaglandins, eicosanoids, and prostacyclin ([@ref5]). This affects and reduces the mucus-buffers-phospholipid layer. Thus, regular aspirin intake interferes with the generation of protective factors necessary for maintaining a barrier to gastric acid ([@ref34]).

The regulation of gastric acid secretion is operated by neuronal, hormonal, and endocrine stimuli affecting the gastric glands of the stomach ([@ref18]) ([Figure 1](#fig1){ref-type="fig"}). The parietal cell is the main player in gastric acid secretion, excreting hydrochloric acid into the lumen by activation of the H^+^, K^+^-ATPase, and various chloride channels, e.g. CFTR, located on the apical surface of the parietal cell ([Figure 1](#fig1){ref-type="fig"}; [@ref17]). Proton pump inhibitors (PPIs), such as omeprazole, serve as the common first line therapy for gastric hypersecretion and acid-related diseases by targeting the H^+^, K^+^-ATPase ([@ref12]). Recently, we identified an additional apical proton extrusion pathway: the vacuolar H^+^-ATPase that is not blocked by PPI therapy ([@ref19]).

![Scheme of the parietal cell of a gastric gland. The scheme explains receptors, ion transporters, and the neuroendocrine regulation of gastric acid secretion ([@ref13]). The components of concentrated hydrochloric acid are secreted by proton pumps (H^+^, K^+^ ATPases) and chloride channels. Aspirin enters the parietal cell from the bloodside (basolateral) and leads to an intracellular increase of the signaling molecule NO, converted by NOS ([@ref21]; [@ref2]; [@ref32]). The increase of NO leads to an increase of sGC, which increases intracellular cGMP levels and ultimately leads to the insertion of the H^+^, K^+^ ATPase on the apical membrane of the parietal cell. The conversion of NO can be inhibited by L-NAME, an analog of arginine, which inhibits NO production. Moreover, the intracellular NO/sGC/cGMP pathway can be inhibited by the sGC-inhibitor ODQ. Intracellular rise in cAMP (by histamine) or Ca^2+^ (by histamine, acetylcholine, Ca^2+^, or gastrin) following the stimulation of the basolateral receptors has a similar effect on the H^+^, K^+^ ATPases like cGMP. The direct neuronal stimulation appears by acetylcholine from the ENS, whereas the hormonal regulation of the parietal cell is dependent on neighboring, histamine-secreting ECL-cells and on G-cells, which secrete gastrin. Gastrin also influences histamine secretion in ECL-cells and leads to an increase of histamine secretion, which is described as the "histamine-gastrin-axis." Somatostatin, secreted by D-cells, decreases intracellular cAMP levels and will stop the insertion and activation of H^+^, K^+^ ATPases.](fphys-10-01264-g001){#fig1}

In this study, we investigated the direct effect of aspirin on the parietal cell and its activation of the H^+^, K^+^-ATPase. We show that aspirin can stimulate the parietal cell and the H^+^, K^+^-ATPase to secrete acid in the absence of known secretagogues. Furthermore, we demonstrate that this aspirin-induced process is *via* activation of NO synthesis within the parietal cell. When either the non-selective NOS inhibitor L-NAME (*N*~ω~-Nitro-L-arginine methyl ester hydrochloride) or the specific sGC inhibitor ODQ was added, the aspirin-induced acid secretion was abolished. In fact, NO signaling is found to be an important pathway in many processes within the cells of the human body ([@ref7]; [@ref25]). Activation of the intracellular receptor NO-GC through NO increases the soluble guanylyl cyclase (sGC) and further to accumulation of cyclic guanosine monophosphate (cGMP) ([@ref9]; [@ref15]; [@ref13]). We hypothesize that aspirin-stimulated gastric acid secretion in parietal cells occurs through the NO/NO-GC/cGMP signaling pathway, which can be inhibited by the non-selective NOS inhibitor L-NAME or the sGC/cGMP-dependent specific inhibitor ODQ.

Materials and Methods {#sec2}
=====================

Tissue Preparation {#sec3}
------------------

Tissue was obtained from male Sprague-Dawley rats with a weight of 250--400 g (Charles River Laboratory), housed in climate and humidity-controlled light-cycled rooms, fed standard chow with free access to water 24 h. Animals were handled according to the humane practices of Animal Care established by the Institutional Animal Care and Use Committee at Yale University. Ethical consent was ensured by the IACUC Approval 2015--07654. Prior to experiments, animals were food deprived for 12--16 h with free access to water. Animals were euthanized with an overdose of isoflurane. Laparotomy and the removal of the stomach were performed. The corpus of the stomach was separated with a longitudinal incision, washed with ice-cold HEPES to remove residual food particles and sliced into 0.2-cm square sections.

Isolation of Gastric Glands {#sec4}
---------------------------

After the corpus was excised and transferred to the stage of a dissecting microscope, individual glands were isolated using the hand-dissection technique as described previously ([@ref31]; [@ref6]). Gastric glands were allowed to adhere to coverslips coated with 0.5 μl of the biological adhesive CellTak (Collaborative Research, MA, USA). The coverslip was attached to a perfusion chamber as previously outlined ([@ref16]).

Digital Imaging for Intracellular pH Measurements {#sec5}
-------------------------------------------------

The isolated gastric glands were incubated in a room tempered HEPES-buffered Ringer's solution containing 10 μM of the pH-sensitive dye BCECF-AM(2′,7′)-bis-(2-carboxyethyl)-5-(and-6)-carboxy-flourescin-acetomethylester (Santa Cruz Biotechnology, TX, USA) for 20 min. Following this, the chamber was placed on the stage of an inverted microscope (Olympus IX50) and flushed with a HEPES-buffered Ringer's solution for at least 5 min to remove residual non-deesterified dye. The chamber was thermostatically controlled at 37°C. The epifluorescence mode with an ×40 objective was used and the BCECF excited at the wavelengths of 490 ± 10 nm and 440 ± 10 nm. Between 6 and 14 regions of interest were outlined per gland. During the experimental cycle, the fluorescent signal was monitored at 530 ± 10 nm every 10 s with the help of an intensified charge-coupled device camera. Individual images and intensity values were recorded along with the emission data showing the 440/490 ratio for real-time intensity measurements ([@ref19]; [@ref4]). At the end of the cycle, cells were calibrated with the High K^+^/Nigericin calibration technique to calculate the pH from the emission data as described in previous studies ([@ref3]).

The recovery of intracellular pH (pH~i~) demonstrates the rate of proton extrusion by individual parietal cells after acid/proton loading using the NH~4~Cl prepulse technique ([@ref19]). Therefore, the cells were superfused with a HEPES-buffered solution containing 40 mM NH~4~Cl. Parietal cells were subsequently flushed with 0Na^+^ solution to eliminate the Na-H-Exchanger (NHE) and trapping protons within the cytosol causing a strong drop of pH. Cells were then flushed with HEPES and finally with the High K^+^ solution. Recovery rates are expressed as ΔpH/min.

Chemicals and Reagents {#sec6}
----------------------

All solutions were adjusted to a temperature of 37°C and a pH of 7.4, with the exception of High K^+^ calibration solution, which was titrated to 7.0. The final osmolality of all solutions was 300 mOsm. All chemicals, including Omeprazole, Carbachol, Aspirin, L-NAME, diethylamine NONOate sodium salt hydrate, and ODQ were obtained from Sigma Aldrich (St. Louis, MO, USA) and J.T. Baker (Phillipsburg, NJ, USA).

Statistical Analysis {#sec7}
--------------------

Data were checked for outliers *via* the ESD method. The unpaired Student's *t*-test and the non-parametric, one way ANOVA-test were performed using the Graphpad/Prism software to analyze differences in pH~i~ recovery rates. ΔpH/min values are presented as mean ± SEM. All results with *p* \< 0.05 were considered significant.

Results {#sec8}
=======

To investigate the direct cellular effect of aspirin on parietal cell acid secretion, we undertook studies using fasted rats with *ad lib* access to fluids ([@ref4]). To assay acid secretion, we used the pH-sensitive dye BCECF to give semi-real time measurements of proton extrusion in glands exposed to aspirin. A very low to negligible basal rate of pH~i~ recovery was observed in the absence of secretagogues (0.0003711 ± 0.0006969 ΔpH/min) (*n* = 66) ([Figure 2A](#fig2){ref-type="fig"}). Superfusing the glands with solutions containing low-dose aspirin (10 μM) induced a stimulatory effect of aspirin-sensitive proton extrusion in the absence of secretagogues resulting in a significant pH~i~ recovery rate (0.0372 ± 0.00629 ΔpH/min) (*n* = 40) ([Figure 2A](#fig2){ref-type="fig"}). The aspirin pH~i~ recovery rate showed a highly significant difference in ΔpH/min compared to non-stimulated conditions, (*p* \< 0.0001) ([Figure 2A](#fig2){ref-type="fig"}). In a separate series, we added the classical secretagogue carbachol (200 μM) to the glands, which induced a robust dose-dependent proton secretion with a significant increase of pH~i~ recovery rate (0.03291 ± 0.002645 ΔpH/min) (*n* = 168) ([Figure 2A](#fig2){ref-type="fig"}). We compared the aspirin-sensitive secretagogue rate to the classical secretagogue carbachol and found comparable rates of proton secretion showing the potency of low-dose aspirin ([Figure 2A](#fig2){ref-type="fig"}). To determine if the aspirin-dependent secretagogue stimulation of acid secretion is omeprazole sensitive, we conducted studies combining aspirin exposure with the PPI omeprazole (200 μM). Adding omeprazole (200 μM) to the low-dose aspirin (10 μM) containing superfusion bath induced a significant inhibition of proton extrusion (−0.000905 ± 0.00121 ΔpH/min) (*n* = 27) ([Figure 2B](#fig2){ref-type="fig"}) to a level comparable to non-stimulated resting controls (0.0003711 ± 0.0006969 ΔpH/min) (*n* = 66) ([Figure 2B](#fig2){ref-type="fig"}) suggesting that the majority of the aspirin effect was *via* the H^+^, K^+^-ATPase. Unsurprisingly, there was no significant difference between the control and the combination of aspirin + omeprazole (*p* = ns), which confirmed that the majority of the effect is *via* the H^+^, K^+^-ATPase ([Figure 2B](#fig2){ref-type="fig"}). To investigate the intracellular pathway for aspirin activation of the parietal cell, we added the non-selective NOS inhibitor L-NAME (30 μM) to our solutions. Our results demonstrate a significant decrease of gastric acid secretion in the presence of L-NAME compared to aspirin-induced gastric acid secretion \[0.0372 ± 0.00629 ΔpH/min (*n* = 40) vs. 0.0004409 ± 0.001308 ΔpH/min (*n* = 85), *p* \< 0.0001\] ([Figure 3A](#fig3){ref-type="fig"}). In a different series of experiments, we examined the potency of L-NAME to inhibit carbachol-induced gastric acid secretion. Results of these studies show that this activation is not NO sensitive \[0.02736 ± 0.001776 ΔpH/min (n = 123) vs. 0.0004409 ± 0.001308 (*n* = 85), *p* \< 0.0001\] ([Figure 3B](#fig3){ref-type="fig"}). Following these studies, we used diethylamine NONOate sodium salt hydrate (1,1-diethyl-2-hydroxy-2-nitroso-hydrazine sodium) (10 μM), a selective NO activator, to confirm the specificity of the novel aspirin finding, that gastric acid secretion can be activated by the intracellular NO pathway. We showed a significant stimulation of the parietal cell acid secretory pathway by the NO donor (0.03115 ± 0.002053 ΔpH/min) (*n* = 182) ([Figure 4](#fig4){ref-type="fig"}). We then used the specific sGC inhibitor ODQ to determine if aspirin activated this part of the NO pathway. These studies shown in [Figure 4](#fig4){ref-type="fig"} demonstrate that aspirin indeed works *via* the NO/sGC/cGMP pathway (0.001641 ± 0.0006249 ΔpH/min) (*n* = 89).

![**(A)** Low-dose aspirin causes gastric acid secretion. Bar graph summarizes the effect of aspirin at 10 μM on resting parietal cells (0.0372 ± 0.00629 ΔpH/min) (*n* = 40). The classical secretagogue carbachol at 200 μM resulted in a comparable rate of pH~i~ recovery (0.03291 ± 0.002645 ΔpH/min) (*n* = 168). Isolated gastric glands of rats were loaded with the pH-sensitive dye BCECF and excited at 490 ± 10 and 440 ± 10 nm. The recovery rate of pH~i~ was calculated from the slope in the absence of Na^+^ after acid loading, using NH~4~Cl prepulse technique. The control shows a low basal proton efflux of the resting parietal cell in the absence of stimulatory agents (0.0003711 ± 0.0006969 ΔpHi/min) (*n* = 66). **(B)** Aspirin-induced gastric acid secretion works *via* the H^+^, K^+^-ATPase. After the application of the PPI omeprazole at 200 μM, results demonstrate a low basal proton efflux of the resting parietal cell in the presence of the stimulatory agent aspirin at 10 μM (−0.000905 ± 0.00121 ΔpHi/min) (*n* = 27).](fphys-10-01264-g002){#fig2}

![**(A)** L-NAME can inhibit aspirin-induced gastric acid secretion. After adding the non-selective NOS inhibitor L-NAME at 30 μM to our solutions, results demonstrate a low basal proton efflux of the resting parietal cell in the presence of the stimulatory agent aspirin (0.0004409 ± 0.001308 ΔpH/min) (*n* = 85). Thus, L-NAME is a potent and significant inhibitor of aspirin-dependent gastric acid secretion (0.0004409 ± 0.001308 vs. 0.0372 ± 0.00629 ΔpH/min, *p* \< 0.0001). **(B)** Carbachol stimulates the parietal cell to secrete gastric acid in the presence of the NOS inhibitor L-NAME. The effect of the classical secretagogue carbachol at 200 μM on rat gastric glands cannot be abolished by the application of the NOS inhibitor L-NAME 30 μM (0.02736 ± 0.001776 ΔpH/min) (*n* = 123). We conclude that aspirin and carbachol differ in the intracellular pathway of the assembly and activation of the H^+^, K^+^-ATPase. Carbachol works through the muscarinic receptor and increases intracellular Ca^2+^ levels, whereas aspirin induces gastric acid secretion through NO.](fphys-10-01264-g003){#fig3}

![Bar graph shows the effect of the direct NO-donor diethylamine NONOate sodium salt hydrate (NONO) at 10 μM and of the sGC-inhibitor ODQ. The application of the NONOate at 10 μM to our solutions resulted in a significant increase of gastric acid secretion (0.03115 ± 0.002053 ΔpH/min) (*n* = 182). By adding the sGC-inhibitor ODQ at 10 μM to the 10 μM NONOate-containing solutions, we were able to abolish this effect completely to the level of basal proton efflux (0.00009813 ± 0.0006929 ΔpH/min) (*n* = 140). Furthermore, a combination of 10 μM aspirin-containing solutions with ODQ at 10 μM resulted in a significantly lower rate than aspirin without ODQ \[0.001641 ± 0.0006249 ΔpH/min (*n* = 89) vs. 0.0372 ± 0.00629 ΔpH/min (*n* = 40), *p* \< 0.0001\]. With the application of the direct NO-donor diethylamine NONOate sodium salt hydrate and the selective sGC inhibitor ODQ, we prove that aspirin-stimulated gastric acid secretion is working *via* the intracellular NO/sGC/cGMP pathway.](fphys-10-01264-g004){#fig4}

We conclude that the novel effect of aspirin causing gastric acid secretion occurs *via* NO signaling and activation of the NO-GC, which further leads to an intracellular increase in the downstream effectors sGC and cGMP. These studies for the first time elucidate a novel effect of aspirin on gastric acid secretion that targets the H^+^, K^+^-ATPase. This activation occurs in the absence of secretagogues suggesting that prior to beginning an aspirin regiment using either normal low-dose aspirin, or enteric coated aspirin, it will be important to use an acid suppression therapy to prevent potential erosions.

Discussion {#sec9}
==========

For over 2,000 years, aspirin (willow root) has been used to treat a variety of conditions ([@ref10]). More recently, it has been used to treat everything from chronic pain to prevention of heart attacks, strokes, and clot formation ([@ref33]). Now, there are substantial reports that aspirin can reduce the risk of a variety of cancers when taken on a daily basis for extended periods of time ([@ref24]). With this further increase in aspiring use comes the potential for increases in patients suffering from gastritis ([@ref1]).

Historically, it has been shown that aspirin leads to modulations in the level of mucous production and that this reduction in mucous may be responsible for the increase in erosions of the lining and the associated gastric bleeds ([@ref20]).

In the present study, we wished to address another potential adverse effect of aspirin namely that it acts as a secretagogue and leads to acid secretion from the gastric glands.

Using an isolated gastric gland preparation, we examined the effects of aspirin delivered to the basolateral membrane of the glands (blood side). When 10 μM aspirin was added to the basolateral perfusate, we observed a significant increase in acid secretion suggesting that as aspirin levels rise in the blood stream they can induce acid secretion even in the absence of the classical secretagogues.

To examine the mechanism, we looked at the NOS pathway as aspirin is known to cause an upregulation in NO production that would lead to activation of the gastric H^+^, K^+^-ATPase (See [Figure 3](#fig3){ref-type="fig"}). This hypothesis was further confirmed in the studies shown in [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} where we employed the NOS inhibitors L-NAME and ODQ (a specific NOS inhibitor). In both cases, there was a complete cessation in aspirin-induced acid secretion.

Our study now shows that should a patient be considered "aspirin sensitive" in that they have acute gastritis that suggesting an enteric aspirin may no longer be sufficient to protect from gastric erosion. We conclude that elevations of aspirin in the bloodstream can lead to acid secretion as aspirin can directly activate the parietal cells *via* the NO pathway. For these reasons, patients wishing to have the beneficial effects of aspirin should consider the inclusion of agents to block acid secretion.
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